Osmotica Pharmaceuticals (NASDAQ:OSMT) Downgraded by BidaskClub

BidaskClub lowered shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a buy rating to a hold rating in a research note released on Thursday morning, BidAskClub reports.

Several other research analysts also recently issued reports on the stock. SunTrust Banks upped their price target on shares of Osmotica Pharmaceuticals from $8.00 to $11.00 and gave the stock a buy rating in a research report on Friday, July 10th. Royal Bank of Canada upped their target price on shares of Osmotica Pharmaceuticals from $10.00 to $12.00 in a research report on Thursday, July 9th. SVB Leerink upped their target price on shares of Osmotica Pharmaceuticals from $8.00 to $10.00 and gave the company an outperform rating in a research report on Friday, July 10th. Wells Fargo & Company restated a hold rating on shares of Osmotica Pharmaceuticals in a research report on Thursday, September 3rd. Finally, Zacks Investment Research downgraded shares of Osmotica Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, August 15th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $8.70.

Shares of Osmotica Pharmaceuticals stock opened at $5.98 on Thursday. The firm has a market capitalization of $308.09 million, a PE ratio of -2.04 and a beta of 3.31. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.17 and a quick ratio of 2.83. The company’s fifty day moving average price is $5.50 and its two-hundred day moving average price is $5.33. Osmotica Pharmaceuticals has a 52-week low of $2.81 and a 52-week high of $9.67.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.06). The business had revenue of $37.53 million during the quarter, compared to the consensus estimate of $38.50 million. Osmotica Pharmaceuticals had a negative net margin of 73.47% and a negative return on equity of 15.61%. Analysts predict that Osmotica Pharmaceuticals will post -0.59 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC acquired a new stake in shares of Osmotica Pharmaceuticals in the 1st quarter valued at approximately $32,000. State of Tennessee Treasury Department raised its position in shares of Osmotica Pharmaceuticals by 175.3% in the 1st quarter. State of Tennessee Treasury Department now owns 10,149 shares of the company’s stock valued at $32,000 after acquiring an additional 6,463 shares during the period. Meeder Asset Management Inc. raised its position in shares of Osmotica Pharmaceuticals by 47.2% in the 1st quarter. Meeder Asset Management Inc. now owns 11,216 shares of the company’s stock valued at $35,000 after acquiring an additional 3,597 shares during the period. Wells Fargo & Company MN raised its position in shares of Osmotica Pharmaceuticals by 144.5% in the 1st quarter. Wells Fargo & Company MN now owns 11,373 shares of the company’s stock valued at $36,000 after acquiring an additional 6,722 shares during the period. Finally, American International Group Inc. increased its stake in Osmotica Pharmaceuticals by 40.2% during the 2nd quarter. American International Group Inc. now owns 7,308 shares of the company’s stock worth $49,000 after purchasing an additional 2,094 shares in the last quarter. Institutional investors and hedge funds own 11.89% of the company’s stock.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Read More: What is Green Investing?

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.